AU StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Avita Therapeutics

2.740

-0.010-0.36%

Volume:273.38K

Turnover:753.98K

Market Cap:421.64M

PE:-0.17

High:2.790

Open:2.740

Low:2.730

Close:2.750

52wk High:2.860

52wk Low:1.000

Shares:153.88M

Float Shares:5.34M

Volume Ratio:0.34

T/O Rate:5.12%

Dividend:- -

Dividend Rate:- -

EPS(TTM):-16.106

EPS(LYR):-19.488

ROE:-1746.27%

ROA:-41.56%

PB:-10.84

PE(LYR):-0.14

Loading ...

Overview Company News Filings

Concept

Pharmaceutical Companies+2.85%

Capital Flow

Inflow:

Outflow:

News

Avita Medical Says Clinical Study for Biosynthetic Wound Matrix Meets Primary Endpoint

MT Newswires Live

Avita Medical Reports Encouraging UK Evaluation of Wound Care System

MT Newswires Live

Avita Medical Posts Narrower Q1 Loss, Higher Revenue; Reaffirms Full-Year 2026 Outlook

MT Newswires Live

Stock Track | Avita Therapeutics Soars 5.35% Intraday on Leadership Appointments

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers HK | Online Trading in stocks, bonds & ETFS","description":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","keywords":"tiger trading,tiger security,tiger broker hk,tigers co ltd,tiger trade hk,tiger brokers hk,stock broker,securities broker,online brokerage,hong kong broker,hk broker,online stock trading,online trading platform,stock trading platforms,trading application,stock trading,stock trading hong kong,buying stocks in hong kong,tiger brokers","social":{"ogDescription":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.atigrdive.com/stock/AVH.AU"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental","symbol":"AVH.AU","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:true,,method:\"POST\",data:#items:@#symbol:\"AVH.AU\",,,,,undefined,":{"symbol":"AVH.AU","market":"AU","secType":"STK","nameCN":"Avita Therapeutics","latestPrice":2.74,"timestamp":1787638320000,"preClose":2.75,"halted":0,"volume":273375,"delay":0,"changeRate":-0.0036363636363635587,"nameEN":"Avita Therapeutics","floatShares":5344505,"shares":153883445,"eps":-16.107974143651656,"marketStatus":"Not Yet Opened","change":-0.01,"latestTime":"08-25 16:12:00 AEST","open":2.74,"high":2.79,"low":2.73,"amount":753980,"amplitude":0.021818,"askPrice":2.76,"askSize":4000,"bidPrice":2.7,"bidSize":7588,"shortable":3,"etf":0,"ttmEps":-16.107974143651656,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":0,"beginTime":1787702400000},"marketStatusCode":0,"adr":0,"adrRate":8,"exchange":"ASX","adjPreClose":2.75,"openAndCloseTimeList":[[1787616000000,1787637600000]],"volumeRatio":0.3372458581163536,"lotSize":1,"tradeCurrency":"AUD","auctionPricing":{"symbol":"AVH.AU","preClose":2.75,"auctionPrice":2.74,"auctionVolume":8400,"auction":3,"marketStatus":"盘后竞价","timestamp":1787638200798}},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:true,,method:\"POST\",data:#items:@#symbol:\"AVH.AU\",,,,,undefined,":{"symbol":"AVH.AU","floatShares":5344505,"roa":"-41.56%","roe":"-1746.27%","lyrEps":-19.48797,"volumeRatio":0.3372458581163536,"shares":153883445,"dividePrice":0,"high":2.79,"amplitude":0.021818,"preClose":2.75,"low":2.73,"week52Low":1,"pbRate":"-10.84","psRate":"3.99","week52High":2.86,"institutionHeld":0,"latestPrice":2.74,"committee":0.309631,"eps":-16.105836601964533,"divideRate":0,"volume":273375,"delay":0,"ttmEps":-16.105836601964533,"open":2.74,"prevYearClose":1.05,"prevWeekClose":2.79,"prevMonthClose":1.295,"prevQuarterClose":1.2,"fiveDayClose":2.2,"twentyDayClose":1.37,"sixtyDayClose":1.175},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/AVH.AU\",params:#limit:5,,,undefined,":[{"market":"AU","date":"2026-08-07","symbol":"AVH.AU","fiscalQuarterEnding":null,"expectedEps":null,"name":null,"time":"","type":"earning","dateTimestamp":1786024800000,"reportTimeType":"","actualEps":null},{"market":"AU","date":"2026-05-15","symbol":"AVH.AU","fiscalQuarterEnding":null,"expectedEps":null,"name":null,"time":"Pre-MKt","type":"earning","dateTimestamp":1778767200000,"reportTimeType":"pre","actualEps":null},{"date":"2023-08-10","symbol":"AVH.AU","type":"earning","reportTimeType":"","market":"AU","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1691625600000,"name":null,"time":"","dateTimestamp":1691589600000,"actualEps":null},{"date":"2023-05-11","symbol":"AVH.AU","type":"earning","reportTimeType":"","market":"AU","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1683763200000,"name":null,"time":"","dateTimestamp":1683727200000,"actualEps":null},{"date":"2023-02-23","symbol":"AVH.AU","type":"earning","reportTimeType":"","market":"AU","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1677106800000,"name":null,"time":"","dateTimestamp":1677070800000,"actualEps":null}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"AVH.AU\",market:\"AU\",,,undefined,":[],"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"AVH.AU\",pageSize:4,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2660186464","title":"Avita Medical Says Clinical Study for Biosynthetic Wound Matrix Meets Primary Endpoint","url":"https://stock-news.laohu8.com/highlight/detail?id=2660186464","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660186464?lang=en_us&edition=fundamental","pubTime":"2026-08-19 07:54","pubTimestamp":1787097259,"startTime":"0","endTime":"0","summary":"Avita Medical  said its multicenter, randomized controlled clinical study for PermeaDerm, a biosynthetic wound matrix, met its primary endpoint, showing statistically significant superiority for mean cost per percent total body surface area treated, according to a Wednesday Australian bourse filing.The study enrolled 40 patients across 11 US burn centers, with wounds of up to 30% total body surface area. After excision, patients were randomized to receive either PermeaDerm or cadaveric allograft during the temporization period before definitive split-thickness skin grafting.Mean treatment cost was AU$148.70 for every 1% total body surface area treated with PermeaDerm, compared with AU$497.10 for allograft, representing a savings of around AU$348 per percent total body surface area.Around 94% of patients treated with PermeaDerm achieved at least 95% graft take one week following autografting, comparable to allograft, and all patients in both groups achieved 95% or greater wound healing ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK7067","AVH.AU","BK7508"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2644032803","title":"Avita Medical Reports Encouraging UK Evaluation of Wound Care System","url":"https://stock-news.laohu8.com/highlight/detail?id=2644032803","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2644032803?lang=en_us&edition=fundamental","pubTime":"2026-06-19 07:33","pubTimestamp":1781825630,"startTime":"0","endTime":"0","summary":"Avita Medical  said its Recell GO wound care system was successfully evaluated in the UK, with investigators reporting healing and complete graft take across a range of burn and reconstructive procedures, according to a late Thursday statement.The medical system prepares a patient's own skin cells into a liquid that can be sprayed directly onto wounds to promote healing.Recell data presented during the British Burn Association's annual meeting also pointed to workflow benefits, including reduced procedural variability, improved consistency of cell preparation, and enhanced operating room efficiency, the company said.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["AVH.AU","BK7067","BK7508"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635793587","title":"Avita Medical Posts Narrower Q1 Loss, Higher Revenue; Reaffirms Full-Year 2026 Outlook","url":"https://stock-news.laohu8.com/highlight/detail?id=2635793587","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635793587?lang=en_us&edition=fundamental","pubTime":"2026-05-15 11:21","pubTimestamp":1778815269,"startTime":"0","endTime":"0","summary":"Avita Medical  reported Friday a March quarter net loss of $0.35 per share, compared with $0.53 a year earlier.Revenue for the three months ended March 31 was $19.3 million, compared with $18.5 million a year earlier.The company reaffirmed its full-year guidance, with revenue expected in the range of $80 million to $85 million.Its shares rose 1% in recent trading on Friday.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK7508","BK7067","AVH.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1147588160","title":"Stock Track | Avita Therapeutics Soars 5.35% Intraday on Leadership Appointments","url":"https://stock-news.laohu8.com/highlight/detail?id=1147588160","media":"Stock Track","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1147588160?lang=en_us&edition=fundamental","pubTime":"2026-05-01 08:11","pubTimestamp":1777594292,"startTime":"0","endTime":"0","summary":"Avita Therapeutics' stock surged 5.35% during intraday trading on Friday, following the announcement of key leadership changes at the company.The medical technology firm appointed Cary Vance as its...","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_en","symbols":["AVH.AU"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":4,"totalPage":3,"pageCount":1,"totalSize":10,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/market/plate/belongs/AVH.AU\",params:#limit:6,delay:true,,,undefined,":[{"market":"AU","name":"Pharmaceutical Companies","id":"package_au_concept_yyswg","bkCode":"BK7508","changeRate":0.0285}]}}